The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) is a key factor involved in coagulation process and plays a vital role in the progression and prognosis of chronic hepatitis B (CHB) patients with antiviral treatment. However, there are few reports about the profile of plasma ADAMTS13 in CHB patients during entecavir maleate (m-ETV) treatment. One hundred two HBV e antigen (HBeAg)–positive CHB patients on continuous m-ETV naive for at least 96 weeks were recruited. Patients with liver cirrhosis were excluded using liver biopsies and real-time elastography. Plasma ADAMTS13 and interleukin 12 (IL-12) levels were evaluated at baseline and12, 24, 48, 72, and 96 weeks, respectively. The change of ADAMTS13 (ΔADAMTS13) and IL-12 (ΔIL-12) possesses a significant relationship in CHB patients with HBeAg seroconversion (SC) at 48-week m-ETV treatment (p < 0.001), but no significance in patients without SC. Furthermore, Cox multivariate analysis demonstrated that the change of ADAMTS13 (IL-12) is an independent predictor for HBeAg SC at week 96, and the area under the receiver operating characteristic curve for the ΔADAMTS13 (ΔIL-12) in CHB patients with 48-week m- ETV treatment is 0.8204 (0.8354) (p < 0.001, both) to predict HBeAg SC at week 96. The results suggested that higher increased ADAMTS13 and IL-12 after 48-week m-ETV treatment contributed to an enhanced probability of HBeAg SC, although the mechanism is undetermined. Quantification of ADAMTS13 (IL-12) during m-ETV treatment may help to predict long-term HBeAg SC in CHB patients.

ADAMTS13（一种具有血小板反应蛋白基序重复 13 次的去整合素和金属蛋白酶）是参与凝血过程的关键因素，在接受抗病毒治疗的慢性乙型肝炎 (CHB) 患者的进展和预后中起着至关重要的作用。然而，关于马来酸恩替卡韦 (m-ETV) 治疗期间慢性乙型肝炎患者血浆 ADAMTS13 分布的报道很少。招募了 102 名 HBV e 抗原 (HBeAg) 阳性的慢性乙型肝炎患者，这些患者连续接受 m-ETV 治疗至少 96 周。使用肝活检和实时弹性成像排除肝硬化患者。分别在基线和 12、24、48、72 和 96 周评估血浆 ADAMTS13 和白细胞介素 12 (IL-12) 水平。p< 0.001)，但在没有 SC 的患者中没有意义。此外，Cox 多变量分析表明 ADAMTS13 (IL-12) 的变化是第 96 周 HBeAg SC 的独立预测因子，以及 48-CHB 患者 ΔADAMTS13 (ΔIL-12) 的受试者工作特征曲线下面积周 m- ETV 治疗为 0.8204 (0.8354) (p< 0.001，两者）预测第 96 周的 HBeAg SC。结果表明，在 48 周的 m-ETV 治疗后更高的 ADAMTS13 和 IL-12 增加了 HBeAg SC 的可能性，尽管机制尚未确定。m-ETV 治疗期间 ADAMTS13 (IL-12) 的量化可能有助于预测 CHB 患者的长期 HBeAg SC。